Brodalumab is a medication used in this clinical trial to treat moderate-to-severe plaque psoriasis. It works by blocking certain proteins in the body that can cause inflammation and lead to the symptoms of psoriasis. The trial is comparing two different ways of using this medication: an adjustable dosage regimen and a standard treatment regimen. The goal is to see which method is more effective in reducing psoriasis symptoms in patients who weigh 120 kg or more.

Plaque Psoriasis – Plaque psoriasis is a chronic autoimmune condition that causes the rapid growth of skin cells, leading to the formation of scales and red patches that can be itchy and sometimes painful. It is the most common form of psoriasis and typically appears as raised, inflamed, and scaly patches on the skin. These patches, or plaques, are often found on the elbows, knees, scalp, and lower back, but they can appear anywhere on the body. The condition can vary in severity, with some individuals experiencing only minor patches, while others may have more extensive skin involvement. The progression of plaque psoriasis can be unpredictable, with periods of remission and flare-ups. Factors such as stress, infections, and certain medications can trigger or worsen the symptoms.